ClinicalTrials.gg
Status unknownNCT04712409SURIDIAB2Updated Aug 17, 2022

Surgical Innovation for Diabetes Treatment 2

An interventional study of Single anastomosis duodeno-ileal bypass and Biliopancreatic diversion with duodenal switch in Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures, Determine Whether BPD With DS or SADI-S as Primary or Revisional Surgery is Superior Than the Other as First Choice for the Superobese and Determine Whether or Not Revision Surgery is as Effective as Primary Surgery and Understand the Physiological Mechanisms Inherent in These Putative Differences, sponsored by Hospital de Sao Sebastiao. Status unknown at 2 sites in Portugal. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-17.

Sponsored by Hospital de Sao Sebastiao · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Aug 2020, registered Jan 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to understand the enteroendocrine physiological changes in superobese patients submitted to two different bariatric procedures (biliopancreatic diversion with duodenal switch versus single anastomosis duodeno-ileal bypass), when perfomed as primary or revisional surgeries (after a sleeve gastrectomy). The main purpose is to establish the metabolic changes obtained with the sleeve gastrectomy and how the revisional procedure maximizes those changes. Additionally, the study will determine whether BPD with DS or SADI-S is superior than the other as first choice for the superobese.

The study will monitor the enteroendocrine function before and after the ingestion of a mixed meal, in pre-operatory and post-surgery timepoints, comparing both primary and revisional surgeries.

Read the detailed description

Abstract Obesity is a chronic disease whose global incidence keeps rising as the twenty first century goes on. Nowadays, the surgical approach constitutes the best treatment option for these patients, making the sleeve gastrectomy and the gastric bypass the more frequently performed bariatric surgeries.

However, the superobese patients (IMC≥ 50kg/m2) present variable weight loss resistance to the previous techniques, showing better results when submitted to disabsorptive procedures, namely the biliopancreatic diversion with duodenal switch, and the more recently created single anastomosis duodeno-ileal bypass. Each constitutes a revisional surgery option after a primary sleeve gastrectomy, reducing surgical and anesthesia risks. This has brought to light that some superobese patients do not need the revisional procedure as they achieve the weight loss target solely by the vertical gastrectomy.

Supported on the investigators' previous work and extensive experience performing both techniques, they now aim to understand the enteroendocrine physiological changes which each procedure accomplishes and compare them in terms of therapeutic efficacy among the superobese. The utmost goals will be to unravel the advantages of BPD-DS and SADI-S as primary or revisional surgeries, the differences between patients that respond well to sleeve gastrectomy alone and those who do not, and, finally, providing further insights on which procedure should be favoured over the other based on the patient characteristics.

Study Overview:

Participants in this study will have been submitted to either BPD-DS or SADI-S, as a primary or as a revisional surgery.

  • Participants visits will be scheduled before surgery and after surgery at 3, 6 , 12 and 24 months for those who receive BPD-DS or SADI-S as a primary procedure.
  • Those who are firstly submitted to the sleeve gastrectomy, visits will be scheduled before surgery and after surgery at 3 , 6 and 12 months. The revisional surgery will take place 1 year after the sleeve, with visits scheduled before surgery and after surgery at 3, 6 and 12 months.

In all these visits, detailed participants assessment will include vitals, anthropometric and biochemical evaluation, and the performance of a MMTT with plasma sampling for hormonal profiles. Intraoperative sampling of visceral and subcutaneous adipose tissue will take place during BPD-DS or SADI-S as a primary procedure and during the sleeve gastrectomy and repeated 1 year after the revisional surgery, either BPD-DS or SADI-S, is performed.

Participant Enrolment:

Participants will be selected from the cohort of patients referred for multidisciplinary evaluation by the clinical team for surgical treatment of obesity of the Centro Hospitalar Entre Douro e Vouga (CHEDV). Participants found to be suitable according to the entry criteria and who have accepted to participate will be enrolled in the study and assigned to one of the four study groups according to participants clinical features.

02

Conditions studied

  • Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures
  • Determine Whether BPD With DS or SADI-S as Primary or Revisional Surgery is Superior Than the Other as First Choice for the Superobese
  • Determine Whether or Not Revision Surgery is as Effective as Primary Surgery and Understand the Physiological Mechanisms Inherent in These Putative Differences

Keywords

  • Bariatric Surgery
  • Superobesity
  • Revisional Bariatric Surgery
  • Single anastomosis duodeno-ileal bypass
  • Biliopancreatic diversion with duodenal switch
03

In context

Lead sponsor

Hospital de Sao Sebastiao is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Bariatric surgery candidates

  • between 45 and 55 kg/m2
  • Aged between 18 and 65 years at surgery

Exclusion criteria

Exclusion Criteria:

  • Previous abdominal surgery
  • Diabetic patients ( A1c > 5,7%) prior to the bariatric procedure
  • Treatment with antidiabetic drugs, except for purposes other than diabetes treatment, prior to the bariatric procedure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    SADI-S as a primary surgery

    Procedure: Single anastomosis duodeno-ileal bypass

  • Active comparator
    BPD-DS as a primary surgery

    Procedure: Biliopancreatic diversion with duodenal switch

  • Active comparator
    SADI-S as a revisional procedure

    Procedure: SADI-S as a revisional procedure

  • Active comparator
    BPD-DS as a revisional procedure

    Procedure: BPD-DS as a revisional procedure

Interventions

  • ProcedureSingle anastomosis duodeno-ileal bypass

    Sleeve gastrectomy followed by division of the duodenum bypassing the jejunum with end-to-side duodeno-ileal diversion

    Also known as: SADI-S

  • ProcedureBiliopancreatic diversion with duodenal switch

    Sleeve gastrectomy, followed by division of the duodenum bypassing the jejunum with end-to-side duedeno-ileal diversion and Roux-en-y entero-enteric anastomosis, leaving 100 cm common channel.

    Also known as: BPD-DS

  • ProcedureSADI-S as a revisional procedure

    In patients previously submitted to sleeve gastrectomy a single anastomosis duodeno-ileal bypass will be performed as 2nd time surgery

  • ProcedureBPD-DS as a revisional procedure

    In patients previously submitted to sleeve gastrectomy a biliopancreatic diversion with duodenal switch will be performed as 2nd time surgery

06

What researchers measure

Primary outcomes

  1. Change in body mass index

    Body mass index (BMI) combines height (in meters) and weight (in kilograms) and is calculated as weight over (height)\^2. Therefore, it will be reported in kg/m\^2. This parameter will be determined at each study timepoint (pre-operatory, 3, 6 and 12 months post-surgery) at presential visits to the clinic.

    Time frame: From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery

  2. Change in glycated haemoglobin

    Glycated haemoglobin (HbA1c) will be measured in percentage (%). This parameter will be assessed at each study timepoint (pre-operatory, 3, 6 and 12 months post- surgery) through routine complete biochemical evaluation.

    Time frame: From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months

  3. Change in glucose dynamic profile

    Glucose will be measured in mmol/L. This parameter will be assessed at each study timepoint (pre-operatory, 3, 6 and 12 months post-surgery) under fasting conditions and during a mixed-meal tolerance teste (MMTT) with blood collection at eight timed intervals (-10, 0, 15, 30, 45, 60, 90 and 120 minutes).

    Time frame: From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months

  4. Change in insulin dynamic profile

    Insulin will be measured in mIU/L. This parameter will be assessed at each study timepoint (pre-operatory, 3, 6 and 12 months post-surgery) under fasting conditions and during a mixed-meal tolerance teste (MMTT) with blood collection at eight timed intervals (-10, 0, 15, 30, 45, 60, 90 and 120 minutes).

    Time frame: From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery

  5. Change in glucagon dynamic profile

    Glucagon will be measured in pmol/L. This parameter will be assessed at each study timepoint (pre-operatory, 3, 6 and 12 months post-surgery) under fasting conditions and during a mixed-meal tolerance teste (MMTT) with blood collection at eight timed intervals (-10, 0, 15, 30, 45, 60, 90 and 120 minutes).

    Time frame: From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery

  6. Change in GLP-1 dynamic profile

    Glucagon-like peptide-1 (GLP-1) will be measured in pmol/L. This parameter will be assessed at each study timepoint (pre-operatory, 3, 6 and 12 months post-surgery) under fasting conditions and during a mixed-meal tolerance teste (MMTT) with blood collection at eight timed intervals (-10, 0, 15, 30, 45, 60, 90 and 120 minutes).

    Time frame: From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery

  7. Change in GIP dynamic profile

    Glucose-dependent insulinotropic polypeptide (GIP) will be measured in pmol/L. This parameter will be assessed at each study timepoint

    Time frame: From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery

Secondary outcomes

  1. Hypertension remission rates

    Time frame: From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery

  2. Dyslipidemia remission rates

    Time frame: From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery

  3. Sleep Apnea remission rates

    Time frame: From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery

  4. Metabolic syndrome remission rates

    Time frame: From enrolment to 12 months post-intervention in 4 visits: preoperative, 3, 6 and 12 months post-surgery

Other outcomes

  1. Surgical morbidity

    Time frame: From surgery date to 3 months post-surgery

  2. Surgical mortality

    Time frame: From surgery date to 3 months post-surgery

  3. Late morbidity

    Time frame: From 3 months until 4 years post-surgery

07

Study locations

2 of 2 sites recruiting
  • São Sebastião Hospital
    Santa Maria Da Feira, Aveiro 4520-211, Portugal
    Recruiting
  • Hospital de São Sebastião
    Santa Maria Da Feira, Portugal
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Aug 2022, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2021
First posted
Jan 15, 2021
StartActual
Aug 16, 2020
Primary completionActual
Aug 16, 2022
CompletionEst.
Feb 1, 2025
Last update
Aug 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04712409
Lead sponsor
Hospital de Sao Sebastiao
Collaborators
Instituto de Ciências Biomédicas Abel Salazar, The Novo Nordisk Foundation Center for Basic Metabolic Research
Responsible party
Marta Guimarães (Principal Investigator, Hospital de Sao Sebastiao) — Principal investigator
First posted
Jan 15, 2021
Start date
Aug 16, 2020
Primary completion
Aug 16, 2022
Completion
Feb 1, 2025 (estimated)
Last update
Aug 17, 2022

Study contacts

Marta Guimarães, PhD
Contact
marta.guimaraes@chedv.min-saude.pt
0034256379700 ext. 5575
Ana Marta Pereira, MD
Contact
amarta.pereira@chedv.min-saude.pt
0034256379700

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion